Pacific Biosciences
PACB
228 hedge funds and large institutions have $1.03B invested in Pacific Biosciences in 2022 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 88 increasing their positions, 61 reducing their positions, and 51 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 61
0.41% less ownership
Funds ownership: 100.89% → 100.48% (-0.41%)
8% less funds holding
Funds holding: 249 → 228 (-21)
19% less call options, than puts
Call options by funds: $7.58M | Put options by funds: $9.38M
33% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 51
49% less capital invested
Capital invested by funds: $2.03B → $1.03B (-$1.01B)
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$33.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.4M |
| 3 |
Two Sigma Advisers
New York
|
+$15.1M |
| 4 |
1WCM
12 West Capital Management
New York
|
+$11.7M |
| 5 |
BlackRock
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$72.7M |
| 2 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$24.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.8M |
| 4 |
Millennium Management
New York
|
-$14.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.7M |
PACB Hedge Fund Activity: Q2 2022 in Review
228 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2022, worth a combined $1.03B — down 49% from $2.03B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of PACB and 34 opened new positions — a net loss of 17 holders — while 61 trimmed existing stakes and 88 added.
The largest buyer was Goldman Sachs, adding an estimated $33.6M. The largest seller was Casdin Capital, exiting entirely with an estimated $72.7M sold.
- 228 institutional investors held Pacific Biosciences (PACB) as of Q2 2022, down from 249 in Q1 2022.
- Funds reported $1.03B of Pacific Biosciences stock for Q2 2022, down 49% quarter-over-quarter.
- 34 funds opened new Pacific Biosciences positions in Q2 2022 and 51 closed out, a net change of -17 holders.
- The largest Pacific Biosciences buyer in Q2 2022 was Goldman Sachs, an estimated $33.6M added.
- The largest Pacific Biosciences seller in Q2 2022 was Casdin Capital, an estimated $72.7M sold.
Based on aggregated 13F filings for Q2 2022.